{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:22:18Z","timestamp":1786969338501,"version":"build-2736575974"},"reference-count":0,"publisher":"Australian Centre for Disease Control","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Commun Dis Intell (2018)"],"abstract":"<jats:p>In Australia, both probable and laboratory-confirmed cases of invasive meningococcal disease (IMD) are reported to the National Notifiable Diseases Surveillance System (NNDSS). When compared to 2023, the number of IMD notifications in 2024 decreased by 5% to 136. IMD was confirmed by laboratory testing in 136\/136 (100%) of 2024 IMD cases, with 63% (86\/136) diagnosed by bacterial culture and 37% (50\/136) by nucleic acid amplification testing. The serogroup was determined for 96% of laboratory-confirmed cases (130\/136): serogroup B (MenB) accounted for 84% of infections (109\/130); MenY for 14% (18\/130); MenW for 1.5% (2\/130) and MenC for 0.8% (1\/130). Finetyping was available on 71% of the cases for which the serogroup was determined (92\/130). In MenB isolates, 21 porA types were detected, the most prevalent of which were P1.7-2,4 (38%; 29\/76) and P1.7,16-26 (11%; 8\/76). In MenY infections, 6 porA types were detected, with P1.5-1,10-1 the dominant porA type (60%; 9\/15); where typed, this was of multilocus sequence type MLST (ST) 1655 and from clonal complex 23 (8\/9). One of the two MenW isolates in 2024 was finetyped and identified as porA type P1.5,2, MLST (ST) 11 and belonging to the clonal complex 11, the hypervirulent strain reported in outbreaks in Australia and overseas. The\u00a0MenC isolate was not typed.\r\nPeaks of IMD occurred in children aged less than 5 years, and in those aged 15\u201324 years, accounting for 20% (27\/136) and 28% (38\/136) of laboratory-confirmed cases respectively. In children aged under 5 years, 92% (24\/26) of IMD was MenB; in those aged 15\u201324 years, 94% (33\/35) of IMD was MenB, with serogroup not determined for one case in those aged &lt; 5 years and three cases aged 15\u201324 years. IMD was reported in all age groups: &lt; 5 years (20%; 27\/136); 5\u20139 years (6%; 8\/136); 10\u201314 years (5%; 7\/136); 15\u201324 years (28%; 38\/136); 25\u201344 years (12%; 16\/136); 45\u201364 years (18%; 25\/136); and in those aged 65 years and older (11%; 15\/136). Whilst MenB predominated in all age groups, the majority of MenY IMD cases were reported in adults aged 45 years and older (14\/18; 78%).\r\nAll cultured IMD isolates (n = 86) had antimicrobial susceptibility testing performed with ceftriaxone and penicillin. Minimum inhibitory concentration (MIC) values were reported using Clinical Laboratory Standards Institute (CLSI) interpretative criteria: 7% (6\/86) were defined as penicillin resistant (MIC value, \u2265 0.5mg\/L); 60% (52\/86) had intermediate susceptibility to penicillin (MIC\u00a0values, 0.125 and 0.25 mg\/L); and 33% (28\/86) were susceptible to penicillin (MIC values, \u2264\u00a00.064\u00a0mg\/L). All isolates tested susceptible to ceftriaxone, ciprofloxacin and rifampicin.<\/jats:p>","DOI":"10.33321\/cdi.2025.49.057","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T20:53:31Z","timestamp":1763412811000},"source":"Crossref","is-referenced-by-count":1,"title":["Australian Meningococcal Surveillance Programme Annual Report, 2024"],"prefix":"10.33321","volume":"49","author":[{"given":"Monica","family":"Lahra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhan","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C R Robert","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan","family":"Van Hal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18788","published-online":{"date-parts":[[2025,11,18]]},"container-title":["Communicable Diseases Intelligence"],"original-title":[],"link":[{"URL":"https:\/\/ojs.cdi.cdc.gov.au\/index.php\/cdi\/article\/download\/3424\/4993","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ojs.cdi.cdc.gov.au\/index.php\/cdi\/article\/download\/3424\/4994","content-type":"application\/vnd.openxmlformats-officedocument.wordprocessingml.document","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ojs.cdi.cdc.gov.au\/index.php\/cdi\/article\/download\/3424\/4993","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T20:53:31Z","timestamp":1763412811000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojs.cdi.cdc.gov.au\/index.php\/cdi\/article\/view\/3424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":0,"URL":"https:\/\/doi.org\/10.33321\/cdi.2025.49.057","relation":{},"ISSN":["2209-6051"],"issn-type":[{"value":"2209-6051","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]}}}